News >

Durvalumab/Tremelimumab Misses Endpoint in Phase III NSCLC Study

Jason M. Broderick @jasoncology
Published: Tuesday, Apr 24, 2018

Sean Bohen, MD, Phd

Sean Bohen, MD, Phd
Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival (OS) compared with standard therapy in heavily pretreated patients with locally-advanced or metastatic non–small cell lung cancer (NSCLC).

The findings come from the phase III ARCTIC study (NCT02352948), which comprised 2 substudies. Substudy A included patients with high PD-L1 expression, and substudy B included patients with PDL1-low/negative tumors. 

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x